An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

Science. 2016 Jan 1;351(6268):77-81. doi: 10.1126/science.aad1283. Epub 2015 Dec 17.

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) infections have led to an ongoing outbreak in humans, which was fueled by multiple zoonotic MERS-CoV introductions from dromedary camels. In addition to the implementation of hygiene measures to limit further camel-to-human and human-to-human transmissions, vaccine-mediated reduction of MERS-CoV spread from the animal reservoir may be envisaged. Here we show that a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels. Compared with results for control animals, we observed a significant reduction of excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge. Protection correlated with the presence of serum neutralizing antibodies to MERS-CoV. Induction of MVA-specific antibodies that cross-neutralize camelpox virus would also provide protection against camelpox.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Camelus / virology*
  • Coronavirus Infections / prevention & control*
  • Coronavirus Infections / veterinary*
  • Disease Outbreaks / prevention & control*
  • Humans
  • Middle East Respiratory Syndrome Coronavirus / physiology*
  • RNA, Viral / immunology
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology*
  • Vaccinia virus / genetics
  • Vaccinia virus / immunology*
  • Viral Vaccines / immunology*
  • Virus Shedding / immunology

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • RNA, Viral
  • Spike Glycoprotein, Coronavirus
  • Viral Vaccines